TD-1473 Dose C ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 97 | 潰瘍性大腸炎 | 2 |
97. 潰瘍性大腸炎
臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03920254 (ClinicalTrials.gov) | July 23, 2020 | 28/3/2019 | TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study | A 3-Year, Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects With Ulcerative Colitis (UC) | Ulcerative Colitis (UC) | Drug: TD-1473 Dose A;Drug: TD-1473 Dose B;Drug: TD-1473 Dose C | Theravance Biopharma | NULL | Terminated | 18 Years | N/A | All | 46 | Phase 2/Phase 3 | United States;Australia;Bulgaria;Canada;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Poland;Portugal;Romania;Serbia;Slovakia;South Africa;Spain;Taiwan;Ukraine |
| 2 | NCT03758443 (ClinicalTrials.gov) | March 11, 2019 | 19/11/2018 | Efficacy & Safety of TD-1473 in Ulcerative Colitis | A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis | Ulcerative Colitis (UC) | Drug: TD-1473 Dose A;Drug: TD-1473 Dose B;Drug: TD-1473 Dose C;Drug: Placebo | Theravance Biopharma | NULL | Terminated | 18 Years | N/A | All | 243 | Phase 2/Phase 3 | Canada;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Poland;Portugal;Romania;Serbia;Slovakia;South Africa;Spain;Taiwan;Ukraine;United States;Bulgaria;Australia |